重要风险提示： 1、公司于2025年1月18日在《中国证券报》《证券时报》和巨潮资讯网（www.cninfo.com.cn）披露了 《2024年度业绩预告》（公告编号：2025-003）。经公司财务部门初步测算（未经审计），预计公司 2024年度归属于上市公司股东的净利润为负值，且扣除后营业收入为14,000万元至18,000万元。根据 《深圳证券交易所股票上市规则》的相关规定，公司股票交易将在2024年年度报告披露后可能被实施退 市风险警示（股票简称前冠以"*ST"字样）。敬请广大投资者注意投资风险。 2、股票异常波动风险 公司分别于2025年4月15日、2025年4月17日披露《股票交易异常波动及风险提示性公告》（公告编号： 2025-015、2025-016）。公司股票（证券简称：双成药业，证券代码：002693）收盘价格涨幅偏离值累 计达到深圳证券交易所的有关规定属于股票交易异常波动情况。近期，公司股票交易价格发生较大波 动，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载 ...

Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]

金十数据4月22日讯，双成药业公告称，公司股票交易价格连续两个交易日收盘价格跌幅偏离值累计超 过20%，属于股票交易异常波动情况。经核实，公司前期披露的信息不存在需要更正、补充之处，近期 公司经营情况及内外部经营环境未发生重大变化，公司及控股股东、实际控制人不存在关于公司的应披 露而未披露的重大事项。公司提醒投资者注意二级市场交易风险，理性决策，审慎投资。同时，公司预 计2024年度归属于上市公司股东的净利润为负值，且扣除后营业收入为1.4亿元至1.8亿元，可能被实施 退市风险警示。 双成药业：目前经营情况正常 未发现应披露而未披露的重大事项 ...

4月22日，南华生物开盘即一字跌停，报8.11元，总市值为26.76亿元。 | 9.07 | | | | --- | --- | --- | | 9.01 | | | | 8.95 | | | | 8,88 | | | | 8.82 | | | | 8.75 | | | | 8.69 | | | | 8.62 | | | | 8,56 | | | | 8.50 | | | | 8.43 | | | | 8,37 | | | | 8.30 | | | | 8.24 | | | | 8.17 | | | | 8,11 | | | | 04/22 | 11:00 | 11:30 | 这一股价变动主要源于公司前一日晚间发布的业绩预告修正公告，即2024年归属于上市公司股东的净利润由预盈1250万–1550万元修正为预亏1900万–2100万 元。 业绩大变脸 | 项目 | 本报告期 | | 上年同期 | 是否修 | | --- | --- | --- | --- | --- | | | 原预计 | 最新预计 | | 正 | | 归属于上市公司 | 盈利: 1,250 万元 | 亏损:1,900 万 元 -2,100 ...

*ST中利（002309）公告，公司2024年度财务报告显示净资产为正值，营业收入23.58亿元，已触发撤销 退市风险警示条件。公司因2023年度净资产为负值及财务报告内部控制否定意见而触及的退市风险警示 和其他风险警示情形已消除。公司已向深圳证券交易所申请撤销相应警示，但申请仍需深交所批准，存 在不确定性。此外，由于公司被中国证监会作出行政处罚决定书未满12个月，仍触及其他风险警示，股 票交易日涨跌幅限制继续为5%。投资者需关注相关风险。 ...

Core Viewpoint - Qinghai Huading Industrial Co., Ltd. faces significant challenges as reflected in its 2024 annual report, with a notable decline in revenue and cash flow, indicating operational and investment strategy difficulties [1] Financial Performance Summary - Revenue decreased by 33.55% to CNY 236,603,674.38 in 2024 from CNY 356,043,035.04 in 2023, attributed to changes in consolidation scope and a drop in orders [2] - The industrial segment's revenue fell by 36.13%, while the newly added natural gas business generated only CNY 8,362,048.94 [2] - Net profit attributable to shareholders was -CNY 89,935,284.53, an improvement from -CNY 159,257,552.49 the previous year, but still in a loss position [2] - The basic earnings per share improved to -CNY 0.20 from -CNY 0.36, reflecting the company's ongoing financial struggles [2] Expense Management - Operating costs decreased by 37.27% to CNY 209,499,954.77, aligning with the revenue decline [3] - Sales expenses dropped by 39.84% to CNY 3,366,971.92, potentially impacting market promotion and sales channel expansion [3] - Financial expenses significantly decreased by 128.59% to -CNY 1,224,522.90, alleviating some financial burden [3] Research and Development - R&D expenses were CNY 11,750,331.61, accounting for 4.97% of revenue, indicating a commitment to innovation despite a reduction in investment [4] - The company has 17 R&D personnel, representing 2.59% of total staff, with an aging workforce that may affect innovation and efficiency [4] Cash Flow Analysis - Operating cash flow was -CNY 70,445,929.55, showing weak cash generation capabilities [5] - Investment cash flow plummeted by 109.56% to -CNY 10,529,027.36, indicating a shift in investment strategy and reduced asset disposal gains [5] - Financing cash flow also worsened to -CNY 75,995,654.82 due to increased debt repayments, intensifying financial pressure [5] Risk and Governance - The company is under delisting risk warning due to negative profit figures and revenue below CNY 300 million, necessitating performance improvement [6][7] - Executive compensation appears reasonable given the company's losses, but the effectiveness of the incentive mechanisms in driving performance remains a concern [7]

青海华鼎（600243）公告，因2024年度经审计的利润总额、净利润或者扣除非经常性损益后的净利润孰 低者为负值且扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入低于3亿元，公司 股票将被上海证券交易所实施退市风险警示。公司股票将于2025年4月22日停牌1天，于2025年4月23日 起实施退市风险警示，股票价格的日涨跌幅限制为5%，并在风险警示板交易。公司股票简称将变更 为"*ST海华"。 ...

Core Viewpoint - ST Tianlong's 2024 annual report reveals significant financial distress, with a sharp decline in revenue and an increase in losses, raising concerns about its operational viability and future prospects [1][4][5]. Financial Performance - The company reported a total revenue of 161 million yuan in 2024, a substantial decrease of 56.26% compared to 368 million yuan in 2023 [4]. - The net profit attributable to shareholders was -27 million yuan, representing an increase in losses by 218.14% year-on-year [4]. - The non-recurring net profit also showed a loss of -27.07 million yuan, down 80.32% from the previous year [4]. - Gross profit for 2024 was 23.17 million yuan, a decline of 20.7% from 29.23 million yuan in 2023, indicating issues in cost control and project profitability [4]. Operational Challenges - Despite adding three new performance projects and renewing seven operation projects, the overall performance remains concerning, suggesting difficulties in business expansion and project execution [1][4]. - The company has faced challenges in converting its investments in the renewable energy sector into revenue growth [4]. Audit and Compliance Issues - The audited net assets for 2024 were reported as negative, and the company has recorded negative net profits for the last three accounting years, leading to a "delisting risk warning" from the Shenzhen Stock Exchange [5]. - The audit report from Zhongxinghua Accounting Firm included a paragraph highlighting significant uncertainty regarding the company's ability to continue as a going concern [5]. Asset Impairment - ST Tianlong recognized asset impairment provisions totaling 16.45 million yuan in 2024, which further pressured its financial performance [6]. - The reasons for asset impairment may relate to underperformance in expected returns from renewable energy projects, despite some projects meeting operational targets [6]. - The frequent occurrence of asset impairment indicates deficiencies in project selection and risk management [6].

万方发展(000638.SZ)公告称，预计2024年度经审计扣除非经常性损益后的 净利润为负值，且扣除后的 营业收入低于3亿元。根据相关规定，公司股票交易可能在2024年年度报告披露后被深圳证券交易所实 施 退市风险警示（股票简称前冠以"*ST"字样）。 ...

上海凯鑫(300899.SZ)公告称，预计2024年度归属于上市公司股东的扣除非经常性损益的 净利润为负值 且扣除后 营业收入低于1亿元，根据相关规定，公司股票交易可能在2024年年度报告披露后被实施 退市 风险警示。具体数据以公司正式披露的经审计后的2024年年度报告为准。 ...